Founded by biopharmaceutical executives, Adam Plich and Anant Murthy, Avanzanite is on a mission to redefine the commercialization of orphan medicines to improve patient access across Europe and beyond. Derived from the word ‘Tanzanite’ – one of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian.
The economic goal is to offer end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets. This is the unique expertise and core competency of our team following decades of operating experience navigating this area.
Equally important, our humanitarian goals stem from our commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where in Europe they live.
Avanzanite Bioscience B.V. is a fully authorized distributor of medicinal products within the European Economic Area, Switzerland and the UK, with a Wholesale Distributor Authorization (WDA) issued by Farmatec in the Netherlands.
The economic goal is to offer end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets. This is the unique expertise and core competency of our team following decades of operating experience navigating this area.
Equally important, our humanitarian goals stem from our commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where in Europe they live.
Avanzanite Bioscience B.V. is a fully authorized distributor of medicinal products within the European Economic Area, Switzerland and the UK, with a Wholesale Distributor Authorization (WDA) issued by Farmatec in the Netherlands.
Location: Netherlands, North Holland, Amsterdam
Employees: 11-50
Total raised: $37.42M
Founded date: 2021
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.11.2025 | Series A | $37.42M | - |
Mentions in press and media 4
| Date | Title | Description |
| 18.11.2025 | Avanzanite Bioscience Raises €32M in Series A Funding | Avanzanite Bioscience, an Amsterdam, the Netherlands-based specialty pharmaceutical company, raised €32M in Series A funding. The round was led by MVM Partners. The company intends to use the funds to accelerate the expansion of its pan-Eur... |
| 18.11.2025 | Avanzanite Bioscience: €32 Million Series A Raised To Accelerate Rare Disease Expansion Across Europe | Avanzanite Bioscience has secured a €32 million Series A investment from MVM Partners, marking the company’s first institutional financing and positioning it for an accelerated phase of commercial and strategic growth across Europe’s rare d... |
| 15.11.2022 | Avanzanite Bioscience Launches Novel Business Model to Commercialize Innovative Medicines for Rare Diseases in Europe | Avanzanite Bioscience B.V. officially launches its commercial-stage enterprise, seeking to expand patient access to medicines for rare diseases in Europe while unlocking revenue and growth potential for emerging research-based biopharmaceut... |
| - | Avanzanite Bioscience | “Avanzanite Bioscience – No One Left Behind” |